Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses future endeavors in the treatment of breast cancer, including triplet combination targeted therapies such as those evaluated in the SUMMIT trial (NCT01953926), as well as recent approvals of novel antibody-drug conjugates such as sacituzumab govitecan. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).